Respuestas rápidas
- ¿Para qué se usa Atezolizumab and hyaluronidase-tqjs?
- La etiqueta aprobada por la FDA (Tecentriq Hybreza, Genentech, Inc., 13 de octubre de 2026) dice, en inglés: “TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. …” Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
- ¿Cuáles son los efectos secundarios de Atezolizumab and hyaluronidase-tqjs?
- La sección «Adverse Reactions» (reacciones adversas) de la etiqueta de la FDA (Tecentriq Hybreza, Genentech, Inc., 13 de octubre de 2026) comienza así, en inglés: «The following clinically significant adverse reactions are described elsewhere in the labeling: Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1)] Infusion-Related Reactions [see Warnings and Precautions (5.2)] Complications of Allogeneic HSCT after PD-1/PD-L1 Inhibitors [see Warnings and Precautions (5.3)] Most common adverse reactions (AR) (≥ 10%) with TECENTRIQ HYBREZA as monotherapy in patients with NSCLC were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
- ¿Atezolizumab and hyaluronidase-tqjs tiene una advertencia en recuadro?
- No. Ninguna de las 1 etiquetas de la FDA que encontramos para este medicamento tiene advertencia en recuadro.
- ¿Hay escasez de Atezolizumab and hyaluronidase-tqjs?
- La FDA no indica una escasez actual para los productos de este medicamento (datos de la FDA del 13 de noviembre de 2026).
- ¿Se ha retirado del mercado Atezolizumab and hyaluronidase-tqjs?
- No aparece ningún retiro vinculado a los productos de este medicamento en los informes de la FDA que usamos.
- ¿Quién fabrica Atezolizumab and hyaluronidase-tqjs?
- 1 empresa tiene productos con receta de Atezolizumab and hyaluronidase-tqjs en el directorio NDC de la FDA, entre ellas Genentech, Inc.
Para qué se usa Atezolizumab and hyaluronidase-tqjs
Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.
TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. …
— Etiqueta de la FDA: Tecentriq Hybreza, Genentech, Inc., vigente desde el 13 de octubre de 2026. Leer la etiqueta completa en DailyMed →
Etiqueta citada: la de la presentación más común (injection, subcutaneous), Tecentriq Hybreza, Genentech, Inc.; abarca 1 producto del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.
Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
Enfermedades que menciona la etiqueta
Estos nombres aparecen tal cual en la sección «Indications and Usage» de la etiqueta (según una tabla revisada). Cada página muestra los hospitales cuyos sitios web mencionan la enfermedad.
Especialidades médicas relacionadas
Advertencia en recuadro
La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.
La etiqueta citada arriba no tiene advertencia en recuadro.
Efectos secundarios de Atezolizumab and hyaluronidase-tqjs
Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.
The following clinically significant adverse reactions are described elsewhere in the labeling: Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1)] Infusion-Related Reactions [see Warnings and Precautions (5.2)] Complications of Allogeneic HSCT after PD-1/PD-L1 Inhibitors [see Warnings and Precautions (5.3)] Most common adverse reactions (AR) (≥ 10%) with TECENTRIQ HYBREZA as monotherapy in patients with NSCLC were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.
Leer más de esta sección
(6.1) Safety of TECENTRIQ HYBREZA for the approved NSCLC, ES-SCLC, HCC, melanoma, ASPS, MIBC, and colon cancer indications is based on safety of intravenous atezolizumab in these populations. Most common AR with intravenous atezolizumab are presented below by indication and regimen (6.1): Most common AR (≥ 20%) as monotherapy were: First-line NSCLC: fatigue/asthenia. Metastatic NSCLC: fatigue/asthenia, cough, decreased appetite, dyspnea, and myalgia/pain. ASPS: musculoskeletal pain, fatigue, rash, cough, headache, nausea, hypertension, vomiting, constipation, dyspnea, dizziness, hemorrhage, diarrhea, insomnia, abdominal pain, hypothyroidism, pyrexia, anxiety, arrhythmia and decreased appetite. MIBC: urinary tract infection. Most common AR (≥ 20%) in combination with other antineoplastic drugs were: NSCLC (with bevacizumab, paclitaxel, and carboplatin): neuropathy, fatigue/asthenia, alopecia, myalgia, nausea, diarrhea, constipation, decreased appetite, arthralgia, hypertension, rash, cough. Non-squamous NSCLC (with paclitaxel protein-bound and carboplatin): fatigue/asthenia, nausea, diarrhea, myalgia/pain, constipation, neuropathy, alopecia, dyspnea, decreased appetite, cough, vomiting and rash. SCLC (with chemotherapy): fatigue/asthenia, nausea, alopecia, decreased appetite, constipation and vomiting. HCC (with bevacizumab): hypertension, fatigue and proteinuria. Melanoma (with cobimetinib and vemurafenib): rash, musculoskeletal pain, fatigue, hepatotoxicity, pyrexia, nausea, pruritus, edema, stomatitis, hypothyroidism, and photosensitivity reaction. Colon cancer (with chemotherapy): nausea, diarrhea, peripheral sensory neuropathy, decreased appetite, abdominal pain, constipation, cough, neuropathy peripheral, dyspnea, stomatitis, vomiting, and pyrexia. To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions of TECENTRIQ HYBREZA in Adult Patients with NSCLC The safety of TECENTRIQ HYBREZA was evaluated in IMscin001, an open-label, multi-center, international, randomized trial for patients with locally advanced or metastatic NSCLC who have not been exposed to cancer immunotherapy and who have had disease progression on prior platinum-based therapy [see Clinical Studies (14.1)].
— Etiqueta de la FDA: Tecentriq Hybreza, Genentech, Inc., vigente desde el 13 de octubre de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →
Dosis de Atezolizumab and hyaluronidase-tqjs
Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.
TECENTRIQ HYBREZA has different recommended dosage and administration than intravenous atezolizumab products. (2.2) TECENTRIQ HYBREZA is for subcutaneous use in the thigh only. (2.2) Do not administer TECENTRIQ HYBREZA intravenously.
Leer más de esta sección
(2.2) The recommended dosage for adult patients and pediatric patients (12 years and older who weigh 40 kg or greater) is: TECENTRIQ HYBREZA 15 mL (1,875 mg atezolizumab and 30,000 units hyaluronidase) subcutaneously into the thigh over approximately 7 minutes every 3 weeks. (2.2) TECENTRIQ HYBREZA must be administered by a healthcare professional. (2.2) NSCLC Dosage In the adjuvant setting, administer TECENTRIQ HYBREZA following resection and up to 4 cycles of platinum-based chemotherapy every 3 weeks for up to 1 year. (2.3) In the metastatic setting, administer TECENTRIQ HYBREZA every 3 weeks. (2.3) When administering with chemotherapy with or without bevacizumab, administer TECENTRIQ HYBREZA prior to chemotherapy and bevacizumab when given on the same day. (2.3) SCLC Dosage Administer TECENTRIQ HYBREZA every 3 weeks. Administer TECENTRIQ HYBREZA prior to chemotherapy when given on the same day. (2.3) HCC Dosage Administer TECENTRIQ HYBREZA every 3 weeks. Administer TECENTRIQ HYBREZA prior to bevacizumab when given on the same day. Bevacizumab is administered intravenously at 15 mg/kg every 3 weeks. (2.3) Melanoma Dosage Following completion of a 28-day cycle of cobimetinib and vemurafenib, administer TECENTRIQ HYBREZA every 3 weeks with cobimetinib 60 mg orally once daily (21 days on /7 days off) and vemurafenib 720 mg orally twice daily. (2.3) ASPS Dosage Administer TECENTRIQ HYBREZA every 3 weeks. (2.3) MIBC Dosage Administer TECENTRIQ HYBREZA after cystectomy every 3 weeks for up to 1 year. (2.3) Colon Cancer Dosage Administer TECENTRIQ HYBREZA every 3 weeks. Administer TECENTRIQ HYBREZA prior to chemotherapy when given on the same day. (2.3) 2.1 Patient Selection for Treatment of Non-Small Cell Lung Cancer, Melanoma, Muscle Invasive Bladder Cancer, and Colon Cancer Select patients with: Stage II to IIIA NSCLC for adjuvant treatment with TECENTRIQ HYBREZA as a monotherapy (following tumor resection and platinum-based chemotherapy) based on PD-L1 expression on tumor cells [see Clinical Studies (14.1)]. Metastatic NSCLC for first-line treatment with TECENTRIQ HYBREZA as monotherapy based on the PD-L1 expression on tumor cells or on tumor-infiltrating immune cells [see Clinical Studies (14.1)]. Unresectable or metastatic melanoma for treatment with TECENTRIQ HYBREZA in combination with cobimetinib and vemurafenib after confirming the presence of a BRAF V600 mutation [see Clinical Studies (14.4)]. MIBC for treatment with TECENTRIQ HYBREZA, as a monotherapy based on detection of ctDNA MRD in plasma via serial testing between six weeks and one year after cystectomy [see Clinical Studies (14.6)].
Tabla de la etiqueta
| Indication | Administration Instructions for TECENTRIQ HYBREZA | Duration of Therapy |
|---|---|---|
| Adjuvant Treatment of Non-Small Cell Lung Cancer | Administer TECENTRIQ HYBREZA as monotherapy | Up to one year, unless there is disease recurrence or unacceptable toxicity |
| Metastatic Non-Small Cell Lung Cancer | Until disease progression or unacceptable toxicity | |
| Non-Small Cell Lung Cancer | Administer TECENTRIQ HYBREZA prior to chemotherapy and bevacizumab when given on the same day. | Until disease progression or unacceptable toxicity |
| Small Cell Lung Cancer | Administer TECENTRIQ HYBREZA prior to chemotherapy when given on the same day. | |
| Hepatocellular Carcinoma | Administer TECENTRIQ HYBREZA prior to bevacizumab when given on the same day. Bevacizumab is administered intravenously at 15 mg/kg every 3 weeks. | |
| Melanoma | Prior to initiating TECENTRIQ HYBREZA, patients should receive the following 28-day treatment cycle of cobimetinib and vemurafenib: Days 1 to 21: cobimetinib 60 mg orally once daily in combination with 960 mg of oral vemurafenib twice daily Days 22 to 28: withhold cobimetinib and administer vemurafenib 720 mg orally twice daily | |
| Alveolar Soft Part Sarcoma | Administer TECENTRIQ HYBREZA as monotherapy | Until disease progression or unacceptable toxicity |
| Muscle Invasive Bladder Cancer | Administer TECENTRIQ HYBREZA as monotherapy | Up to one year, unless there is disease recurrence or unacceptable toxicity |
| Colon Cancer | Administer TECENTRIQ HYBREZA prior to chemotherapy when given on the same day. | In combination with chemotherapy for 6 monthsIf induction chemotherapy is discontinued early, the total TECENTRIQ HYBREZA treatment should not exceed 12 months., followed by TECENTRIQ HYBREZA as monotherapy for 6 months or until disease recurrence or unacceptable toxicity |
— Etiqueta de la FDA: Tecentriq Hybreza, Genentech, Inc., vigente desde el 13 de octubre de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →
Atezolizumab and hyaluronidase-tqjs en el embarazo
Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.
Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1)], TECENTRIQ HYBREZA can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ HYBREZA in pregnant women. Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus resulting in fetal death (see Data).
Leer más de esta sección
Advise females of reproductive potential of the potential risk to a fetus [see Warnings and Precautions (5.4)]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data: TECENTRIQ HYBREZA for subcutaneous injection contains atezolizumab and hyaluronidase [see Description (11)]. Atezolizumab: Animal reproduction studies have not been conducted with atezolizumab to evaluate its effect on reproduction and fetal development. A literature-based assessment of the effects on reproduction demonstrated that a central function of the PD-L1/PD-1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to a fetus. Blockage of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to a fetus and to result in an increase in fetal loss; therefore, potential risks of administering atezolizumab during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-L1/PD-1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to atezolizumab may increase the risk of developing immune-mediated disorders or altering the normal immune response. Hyaluronidase: In an embryo-fetal study, mice were dosed daily by subcutaneous injection during the period of organogenesis with hyaluronidase (recombinant human) at dose levels up to 2,200,000 U/kg, which is > 2,400 times higher than the human dose. The study found no evidence of teratogenicity. Reduced fetal weight and increased numbers of fetal resorptions were observed, with no effects found at a daily dose of 360,000 U/kg, which is > 400 times higher than the human dose. In a peri- and post-natal reproduction study, mice have been dosed daily by subcutaneous injection, with hyaluronidase (recombinant human) from implantation through lactation and weaning at dose levels up to 1,100,000 U/kg, which is > 1,200 times higher than the human dose. The study found no adverse effects on sexual maturation, learning and memory or fertility of the offspring.
— Etiqueta de la FDA: Tecentriq Hybreza, Genentech, Inc., vigente desde el 13 de octubre de 2026. Leer la etiqueta completa en DailyMed →
Cuándo no se debe usar Atezolizumab and hyaluronidase-tqjs
Cita de la sección «Contraindications» (contraindicaciones) de la etiqueta aprobada por la FDA. Se muestra en inglés.
TECENTRIQ HYBREZA is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients. TECENTRIQ HYBREZA is contraindicated in patients with known hypersensitivity to hyaluronidase or any of its excipients. (4)
— Etiqueta de la FDA: Tecentriq Hybreza, Genentech, Inc., vigente desde el 13 de octubre de 2026. Leer la etiqueta completa en DailyMed →
Presentaciones y vía de administración
| Formas farmacéuticas | Inyección |
|---|---|
| Vía | Subcutánea |
| Productos con receta | 1 en el directorio NDC de la FDA |
| Nombres de marca | Tecentriq Hybreza |
Empresas que tienen este medicamento
Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.
- Genentech, Inc.1 producto
Historial de aprobación de la FDA
- BLA: Solicitud de licencia de productos biológicos (BLA): así se aprueba un medicamento biológico (hecho a partir de células vivas).
| Solicitud | Patrocinador | Aprobada | Cambios aprobados después |
|---|---|---|---|
| BLA761347 TECENTRIQ HYBREZA | Genentech Inc | 12 de septiembre de 2024 | 7, el último 8 de octubre de 2026 2026: Eficacia · 2026: Eficacia · 2026: Etiquetado |
Escasez
La lista de escasez de la FDA no incluye estos productos.
Retiros del mercado
No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.
Identificadores oficiales
| RxCUI (RxNorm) | 2693892, 2693899 |
|---|---|
| ID (SPL set ID) de la etiqueta citada | a617b089-ce66-464b-987b-b45d029b4d6f |
| Etiquetas de la FDA (SPL) | 1 |
| Solicitudes de la FDA | BLA761347 |
| Principios activos (FDA) | ATEZOLIZUMAB / HYALURONIDASE (HUMAN RECOMBINANT) |
Siguientes pasos
- Encuentre una farmacia cerca de ustedPregunte qué precio le corresponde y si su producto está afectado por un retiro
- Últimos retiros de medicamentos de la FDATodos los medicamentos, los más recientes primero
- Cáncer de pulmónEnfermedad que menciona la etiqueta: hospitales que la tratan
- Genentech, Inc.Fabricante o distribuidor
- Todos los medicamentos con receta de la A a la ZBusque por nombre genérico, de marca o en español
Fuentes
- Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Tecentriq Hybreza, Genentech, Inc., vigente desde el 13 de octubre de 2026; vía openFDA, datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →
Informar un error → · Información para fabricantes de medicamentos